AstraZeneca AZN announced that the FDA expanded the label of its blockbuster cancer drug Imfinzi for a fourth indication in lung cancer. The FDA approved Imfinzi in combination with platinum-based ...
A Roche cancer drug that treats lung cancer with a certain genetic signature now has an additional FDA approval that expands the applications of the blockbuster product. The drug, Alecensa, is already ...
The ENCORE results could see Insmed's Arikayce move up the MAC lung infection treatment paradigm to earlier lines. Credit: Grayson450 / Shutterstock.com. · Clinical Trials Arena · Grayson450 / ...
Insmed is looking to expand the role of its inhaled Mycobacterium avium complex (MAC) lung disease therapy, Arikayce (amikacin), following the drug’s success in a Phase IIIb trial. In the ENCORE study ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results